CompletedNot Applicable

Combination of Rectal Indomethacin and Pancreatic Duct Stenting Versus Indomethacin Alone in Preventing PEP

China664 participantsStarted 2020-01-01

Plain-language summary

Rectal indomethacin and pancreatic duct (PD) stenting (PDS) are recommended for the prevention of post-ERCP pancreatitis (PEP). However, the effects of the combination of the two methods on preventing PEP are controversial. We hypothesized that some group of patients with difficult cannulation might benefit from the combination of indomethacin plus PDS (IP) compared with indomethacin alone (IN).

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients underwent diagnostic or therapeutic ERCP
✓. With native papilla
✓. With difficult cannulation (cannulation time \>10min or cannulation attempts \>5 times or inadvertently PD cannulation ≥1)
✓. Receiving post-ERCP rectal indomethacin

Exclusion criteria

✕. Patients with indications of PD cannulation
✕. No attempt of cannulation due to inaccessible papilla
✕. Non-difficult cannulation

What they're measuring

Overall PEP

Timeframe: 30 days

Trial details

NCT IDNCT04340687

SponsorAir Force Military Medical University, China

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-03-01

View on ClinicalTrials.gov More Healthy trials